CD38 and acute lymphoblastic leukemia: In two patients, we could detect most of the known oncogenic mutations in CD34+CD38− multipotent progenitor cells and in myeloid progenitors, providing evidence that mutations in some T-ALL patients start to accumulate in multipotent progenitor/stem cells.